ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

SGMT vs GYRE // EV/EBITDA & P/E VALUATION

Sagimet Biosciences Inc. (Series A) (NASDAQ) VS. Gyre Therapeutics Inc. (NASDAQ) • 15-METRIC TALLY: SGMT 2 — GYRE 3
■ METRIC PARITY
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (SGMT VS. GYRE) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC SGMT GYRE SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin — 95.40% — TIE /gross-margins <GO>
Return on Invested Capital (ROIC) -35.00% 25.40% -60.40 GYRE /roic <GO>
EV/EBITDA & P/E Valuation ACTIVE — 53.3x — TIE /valuation <GO>
Free Cash Flow Yield -6.21% -0.03% -6.18 GYRE /fcf-yield <GO>
Operating Margin — 9.90% — TIE /operating-margins <GO>
Net Profit Margin — 8.50% — TIE /net-margins <GO>
Revenue Growth (YoY) — 10.20% — TIE /revenue-growth <GO>
Dividend Yield & FCF Payout Safety 0.00% 0.00% 0.00 TIE /dividend-safety <GO>
Altman Z-Score & Debt/Equity — 14.33 — TIE /balance-sheet <GO>
Piotroski F-Score Quality 2/9 5/9 -3.00 GYRE /piotroski-score <GO>
Options Implied Move & Put/Call Skew — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum 53.2 29.5 +23.65 SGMT /rsi-technicals <GO>
10Y Yield & FRED Macro Beta — — — TIE /macro-sensitivity <GO>
Forward P/E Multiple — 67.2x — TIE /forward-pe <GO>
Enterprise Scale & Market Cap $735.7M $714.8M $20.9M SGMT /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR SGMT REV GYRE REV SGMT GROSS % GYRE GROSS % SGMT FCF GYRE FCF
FY 2025 $0 $116.6M — 95.4% -$45.6M -$180.0K
FY 2024 $0 $105.8M — 96.3% -$42.4M -$6.0M
FY 2023 $2.0M $113.5M — — -$23.8M $25.9M
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
SGMT // BETA —
GYRE // BETA —